• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

This Major Strategic Analysis Provides a Detailed Insight Into the Current and Future Market for Targeted Drug Delivery Technology

Posted on: Monday, 26 November 2007, 06:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c75398) has announced the addition of "Targeted Drug Delivery Technologies: Players, Products & Prospects to 2015" to their offering.

Providing ...

Critical analyses and competitive ratings for major specialist developers Unique sales forecasts to 2015 for key current and new products utilising targeted drug delivery technologies A comprehensive examination of this major drug delivery sector

Whilst many approved and developmental drugs are well-tolerated, numerous drugs need advanced delivery technologies to improve pharmacokinetics, decrease toxicity, increase tolerability and ultimately enhance the therapeutic index. Peripheral toxicity related to the systemic administration of compounds can be dose limiting. However, the application of drug carrier platforms (dendrimers, liposomes, polymers, micelles) can significantly improve bio-distribution, whilst the addition of a targeted ligand (antibodies, peptides, proteins, vitamins) can enhance the selective uptake of drugs to target tissues or cells, thereby minimizing non-specific binding to non-target tissue.

It is estimated that the advanced drug delivery market was worth around US$6.5 billion in 2006 with around 50% derived from targeted carrier systems and the remainder derived from implants and intrauterine devices. Advances in polymer technologies have enabled delivery specialists to design carriers for targeted delivery either through direct drug conjugates or through polymer formulations. However, one vehicle may not meet all delivery needs and progress in liposome formulations has also met with considerable success.

The role of Mabs

Some developers have chosen to harness the natural ability of monoclonal antibodies to target cells and where they may not make the grade as an immunotherapeutic, they may become useful carriers for drugs and the delivery of diagnostics and radiation. In addition, an array of antibody fragments and other gene targeting agents (aptamers, oligonucleotides) are also under investigation as targeting ligands for delivery.

This report identifies 25 companies which have active research and clinical programmes evaluating targeted delivery carriers. By 2015 we anticipate 15 of these companies may have new or improved formulations of approved products on the market that will help to address the high unmet clinical need for "targeted" therapies. It is anticipated that nearly 30 new products will enter the market to generate an additional US$2 billion in advanced drug delivery sales. These products cover a number of key therapy areas including, cancer, cardiovascular and infectious disease.

Combination products are the future

Over time the line between each delivery system will become blurred as combination delivery systems evolve to meet the specific needs for each therapy class. As advances in nanotechnologies help to miniaturize delivery platforms, developments in targeting vehicles will grow to ensure the specific and selective intracellular and intranuclear delivery -- providing the right drug at the right time to the right cell.

About the Author

Dr Cheryl Barton is a highly regarded independent consultant with over 15 years' research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synthélabo, and assessed the potential impact of new drug development on European Stocks.

Executive Summary

Introduction

Overview of delivery technologies for systemic targeted delivery: past, present & future

Systemic targeted delivery technologies

Strategies of drug delivery companies

The targeted delivery market

Competitor analysis

Company profiles

Appendix 1

Appendix 2

Appendix 3

Bibliography

Glossary

Acronyms

For more information visit http://www.researchandmarkets.com/reports/c75398.

Source: Espicom Business Intelligence Ltd.

Source: Business Wire

More News in this Category